According to recent announcements, BIOHEART-B (02185) has revealed that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully completed market access and the first commercial procedure for the Iberis® Radial Denervation System (IBERIS® RDN System) in Switzerland. This procedure was conducted at the University Hospital of Basel, with no reported complications or adverse events. The case received joint support from Borsham International Group Ltd. (Borsham) and Antong. Antong and Borsham have formed a strategic partnership for the commercialization of the Iberis® RDN System, covering several regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM). As of this announcement, the Iberis® RDN System is the only renal denervation (RDN) product globally authorized for use via the transradial approach (TRA) and transfemoral approach (TFA). The TRA makes RDN safer, more effective, and more cost-efficient. The company's ultimate goal is to provide outpatient RDN surgeries for patients worldwide. Antong acquired the CE mark for the Iberis® RDN System in Europe in 2016.